Abstract
To evaluate the efficacy of current treatments for the Raynaud phenomenon (RP) in patients with systemic sclerosis (SSc), a systematic literature search was performed using Medline, EMBASE, and Cochrane Central Register of Controlled Trials (from 1961 to October 2011). We included meta-analyses, systematic reviews, clinical trials, and high-quality cohort studies published in English or Spanish. Patient populations had to include adults diagnosed with limited cutaneous or diffuse SSc who had associated RP and/or digital ulcers under pharmacological treatment. Efficacy of treatments was evaluated based on: number of RP episodes, RP severity, episode-free time, ulcer improvement/healing, and appearance of new ulcers. We used the Jadad scale of methodological quality to evaluate the quality of randomized clinical trials, and the 2009 Oxford Centre for Evidence-Based Medicine classification for other studies. Of a total of 1617 studies identified, only 27 fulfilled inclusion criteria. Drugs received the following grade recommendations: Grade A for nifedipine, nicardipine, quinapril, IV iloprost, bosentan, tadalafil, and MQx-503; Grade B for beraprost, cicaprost, DMSO, cyclofenil, and atorvastatin; and Grade C for misoprostol, prazosin, OPC-2826, enalapril, sildenafil, antioxidant, and stanazolol. Calcium channel blockers, prostanoids, tadalafil, and bosentan received the highest recommendation level for their effectiveness. However, most systematic reviews reviewed just a handful of studies with small sample sizes and short follow-ups. Our review shows that the existing evidence on the efficacy of RP treatment in SSc patients is inconclusive which calls for further research, especially in the form of prospective studies of high quality with long-term follow-ups.
Similar content being viewed by others
References
Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620–628
Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M (2001) Oxford centre for evidence-based medicine levels of evidence. BJU Int 2009 104:1825
Jadad AR, Moore RA, Caroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials is blinding necessary? Control Clin Trials 17:1–12
Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841–1847
Kallenberg CG, Wouda AA, Kuitert JJ, Tijssen J, Wesseling H (1987) Nifedipine in Raynaud’s phenomenon: relationship between immediate, short term and longterm effects. J Rheumatol 14:284–290
Thomas RHM, Rademaker M, Grimes SM, MacKay A, Kovacs IB, Cook ED, Bowcock SM, Kirby JD (1987) Nifedipine in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis. Br J Dermatol 117:237–241
Varela-Aguilar JM, Sánchez-Román J, Talegón MA, Castillo PMJ (1997) Comparative study of misoprostol and nifedipine in the treatment of Raynaud’s phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex. Rev Clin Esp 197:77–83
Janini SD, Scott DG, Coppock JS, Bacon PA, Kendall MJ (1988) Enalapril in Raynaud’s phenomenon. J Clin Pharm Ther 13:145–150
Gliddon AE, Doré CJ, Black CM, McHugh N, Moots R, Denton CP et al (2007) Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 56:3837–3846
Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells GA et al (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000953
Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG et al (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298:561–564
Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M et al (1998) Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 41:670–677
Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ et al (1998) Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 37:952–960
Vayssairat M (1999) Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 26:2173–2178
Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503–508
Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993
Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32–38
Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N (2010) Effect of the dual endothelin receptor antagonist bosentan on Raynaud’s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford) 49:583–587
Fries R, Shariat K, von Wilmowsky H, Böhm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985
Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE et al (2009) Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol 36:2264–2268
Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R et al (2010) Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 49:2420–2428
Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000956
Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells GA, Silman A (2000) Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000954
Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, Kambayashi J et al (2004) Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 50:3994–4001
Surwit RS, Gilgor RS, Allen LM, Duvic M (1984) A double-blind study of prazosin in the treatment of Raynaud’s phenomenon in scleroderma. Arch Dermatol 120:329–331
Russell IJ, Lessard JA (1985) Prazosin treatment of Raynaud’s phenomenon: a double blind single crossover study. J Rheumatol 12:94–98
Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S et al (2009) MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial. Arthritis Rheum 60:870–877
Williams HJ, Furst DE, Dahl SL, Steen VD, Marks C, Alpert EJ et al (1985) Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis Rheum 28:308–314
Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Cyclofenil for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000955
Tingey PC, Harding SE, Pope J, Fenlon D, Furst D, Shea B et al (2000) Cyclofenil for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000955
Blom-Bulow B, Oberg K, Wollheim FA, Persson B, Jonson B, Malmberg P et al (1981) Cyclofenil versus placebo in progressive systemic sclerosis. A one-year double-blind crossover study of 27 patients. Acta Medica Scandinavica 210:419–428
Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol 35:1801–1808
Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K et al (2000) A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349–356
Jayson MI, Holland CD, Keegan A, Illingworth K, Taylor L (1991) A controlled study of stanozolol in primary Raynaud’s phenomenon and systemic sclerosis. Ann Rheum Dis 50:41–47
Acknowledgments
We thank Hosanna Soler Vila, PhD., for her contribution to this manuscript as medical writer. This work was funded by the Spanish Rheumatology Foundation through a non-restricted grant by ROCHE.
Conflict of interest
Dr. García de la Peña Lefebvre has no conflict of interest. Dr. Nishishinya has no conflict of interest. Dr. Pereda has no conflict of interest. Dr. Loza reports grants from Roche, Abbvie, BMS, Pfizer, Tigenix, MSD and Novartis. Dr. Sifuentes Giraldo has no conflict of interest. Dr. Román Ivorra has been speaker for Roche, Pfizer and BMS, advisory Group member: for Actelion, and clinical researcher for Abbvie, MSD and UCB. Dr. Carreira has no conflict of interest. Dr. Rúa-Figueroa has no conflict of interest. Dr. Pego-Reigosa was supported by BIOCAPS from the European Union 7th Framework Programme/REGPOT-2012-2013.1 (grant number 316265). Dr. Muñoz-Fernández has no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
García de la Peña Lefebvre, P., Nishishinya, M.B., Pereda, C.A. et al. Efficacy of Raynaud’s phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. Rheumatol Int 35, 1447–1459 (2015). https://doi.org/10.1007/s00296-015-3241-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-015-3241-1